Pfizer and its German partner BioNTech on Tuesday requested emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a second COVID-19 booster dose for seniors. This would be the fourth dose to the regimen of the Pfizer-BioNTech (Pfizer) COVID-19 vaccines for those aged 65 and over. In the United States, the primary series of the Pfizer COVID-19 vaccine is currently authorized for those aged 12 and over, and one booster dose at least five months later is authorized for those aged 18 and over. Two Data Sets Cited Pfizer and BioNTech said in a release their FDA submission is based on two real-world data sets from Israel “analyzed at a time when the Omicron variant was widely circulating.” In Israel, a second booster is now authorized for many people over 18. The companies said that both data sets “showed evidence that an additional mRNA booster increases immunogenicity and lowers rates of confirmed …